Published in Brain Pathol on April 01, 2004
Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer (2008) 3.98
The quest for the 1p36 tumor suppressor. Cancer Res (2008) 1.95
Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins. Nat Rev Cancer (2010) 1.93
Molecular diagnostics of gliomas: state of the art. Acta Neuropathol (2010) 1.40
1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas. Oncogene (2007) 1.12
Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. Clin Cancer Res (2009) 1.11
Loss of NOTCH2 positively predicts survival in subgroups of human glial brain tumors. PLoS One (2007) 1.11
Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors. J Mol Diagn (2006) 1.09
Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol Appl Neurobiol (2012) 1.08
Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51. Int J Radiat Oncol Biol Phys (2011) 1.07
Clonal analysis in recurrent astrocytic, oligoastrocytic and oligodendroglial tumors implicates IDH1- mutation as common tumor initiating event. PLoS One (2012) 1.05
'Putting our heads together': insights into genomic conservation between human and canine intracranial tumors. J Neurooncol (2009) 1.01
Biology, genetics and imaging of glial cell tumours. Br J Radiol (2011) 1.00
The importance of 10q status in an outcomes-based comparison between 1p/19q fluorescence in situ hybridization and polymerase chain reaction-based microsatellite loss of heterozygosity analysis of oligodendrogliomas. J Neuropathol Exp Neurol (2012) 0.92
Incorporation of prognostic and predictive factors into glioma clinical trials. Curr Oncol Rep (2013) 0.91
Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment. Neoplasia (2005) 0.88
The tumor suppressor Chd5 is induced during neuronal differentiation in the developing mouse brain. Gene Expr Patterns (2013) 0.86
Intratumoral patterns of clonal evolution in gliomas. Neurogenetics (2009) 0.86
Molecular neuropathology of gliomas. Int J Mol Sci (2009) 0.83
Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments. Curr Oncol Rep (2011) 0.83
1p/19q testing has no significance in the workup of glioblastomas. Neuropathol Appl Neurobiol (2013) 0.83
A "weighted" fluorescence in situ hybridization strengthens the favorable prognostic value of 1p/19q codeletion in pure and mixed oligodendroglial tumors. J Neuropathol Exp Neurol (2013) 0.82
Detection of 1p19q deletion by real-time comparative quantitative PCR. Biomark Insights (2012) 0.81
Characterization and gene expression profiling in glioma cell lines with deletion of chromosome 19 before and after microcell-mediated restoration of normal human chromosome 19. Genes Chromosomes Cancer (2009) 0.78
Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas. J Neurooncol (2017) 0.77
Differential proteome analysis of human gliomas stratified for loss of heterozygosity on chromosomal arms 1p and 19q. Neuro Oncol (2010) 0.76
Hsp27 (HSPB1): a possible surrogate molecular marker for loss of heterozygosity (LOH) of chromosome 1p in oligodendrogliomas but not in astrocytomas. Cell Stress Chaperones (2012) 0.76
Something old and something new about molecular diagnostics in gliomas. Surg Pathol Clin (2012) 0.75
Comparative studies of TIMP-1 immunohistochemistry, TIMP-1 FISH analysis and plasma TIMP-1 in glioblastoma patients. J Neurooncol (2016) 0.75
ZNF545 suppresses human hepatocellular carcinoma growth by inhibiting NF-kB signaling. Genes Cancer (2017) 0.75
The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 49.11
International network of cancer genome projects. Nature (2010) 20.35
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature (2012) 10.99
The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol (2002) 8.62
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol (2009) 7.73
Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet (2009) 7.62
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 6.71
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol (2012) 6.20
Dissecting the genomic complexity underlying medulloblastoma. Nature (2012) 4.77
Long-term survival with glioblastoma multiforme. Brain (2007) 4.51
Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol (2005) 4.35
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol (2009) 4.32
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature (2012) 4.04
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest (2008) 3.98
Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. J Nucl Med (2012) 3.67
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol (2011) 3.66
Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol (2009) 3.65
MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol (2009) 3.32
International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol (2014) 3.21
Histological classification and molecular genetics of meningiomas. Lancet Neurol (2006) 3.19
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 3.05
Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. Cancer Res (2007) 3.05
Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol (2009) 3.01
Silent and apparent cerebral embolism after retrograde catheterisation of the aortic valve in valvular stenosis: a prospective, randomised study. Lancet (2003) 2.86
Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res (2008) 2.84
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol (2010) 2.71
Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol (2009) 2.67
A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain (2010) 2.49
Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood (2011) 2.44
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet (2013) 2.42
Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am J Pathol (2003) 2.38
O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain (2005) 2.37
Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn (2007) 2.35
EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell (2013) 2.28
SNP-based analysis of genetic substructure in the German population. Hum Hered (2006) 2.21
Systemic complement activation in age-related macular degeneration. PLoS One (2008) 2.18
Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol (2012) 2.17
Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol (2003) 2.14
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol (2007) 2.11
The "diffuse-trickling" fundus autofluorescence phenotype in geographic atrophy. Invest Ophthalmol Vis Sci (2014) 2.06
Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study. Med Microbiol Immunol (2007) 2.04
The neuronal transporter gene SLC6A15 confers risk to major depression. Neuron (2011) 2.02
Risk and fate of cerebral embolism after transfemoral aortic valve implantation: a prospective pilot study with diffusion-weighted magnetic resonance imaging. J Am Coll Cardiol (2010) 1.98
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology (2013) 1.98
Safety of brain 3-T MR imaging with transmit-receive head coil in patients with cardiac pacemakers: pilot prospective study with 51 examinations. Radiology (2008) 1.91
Tidal recruitment assessed by electrical impedance tomography and computed tomography in a porcine model of lung injury*. Crit Care Med (2012) 1.84
Association of a polymorphism of the ACVRL1 gene with sporadic arteriovenous malformations of the central nervous system. J Neurosurg (2006) 1.83
Chromosome 7p11.2 (EGFR) variation influences glioma risk. Hum Mol Genet (2011) 1.83
Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol (2005) 1.83
Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline. J Neuropathol Exp Neurol (2003) 1.82
Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes. Acta Neuropathol (2010) 1.82
A new clinico-pathological classification system for mesial temporal sclerosis. Acta Neuropathol (2007) 1.77
Mechanisms of Disease: cancer stem cells--targeting the evil twin. Nat Clin Pract Oncol (2008) 1.74
Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol (2008) 1.74
Tau EGFP embryonic stem cells: an efficient tool for neuronal lineage selection and transplantation. J Neurosci Res (2002) 1.71
Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussen's encephalitis. Ann Neurol (2002) 1.71
Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro Oncol (2012) 1.68
Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group. J Urol (2004) 1.68
Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer (2007) 1.67
Memory outcome after selective amygdalohippocampectomy in patients with temporal lobe epilepsy: one-year follow-up. Epilepsia (2004) 1.66
Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system. Acta Neuropathol (2010) 1.65
Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. J Clin Oncol (2010) 1.65
Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res (2005) 1.63
Pten signaling in gliomas. Neuro Oncol (2002) 1.62
Frequent recurrence and progression in pilocytic astrocytoma in adults. Cancer (2007) 1.62
Focal cortical dysplasia of Taylor's balloon cell type: mutational analysis of the TSC1 gene indicates a pathogenic relationship to tuberous sclerosis. Ann Neurol (2002) 1.61
Vowel articulation in Parkinson's disease. J Voice (2010) 1.61
Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival. Clin Cancer Res (2009) 1.61
Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer (2011) 1.61
Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol (2002) 1.61
Genetic risk profiles identify different molecular etiologies for glioma. Clin Cancer Res (2010) 1.59
Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol (2003) 1.57
The natural history of Rasmussen's encephalitis. Brain (2002) 1.57
Diagnosis and treatment of primary CNS lymphoma. Nat Rev Neurol (2013) 1.56
Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol (2004) 1.55
Astrocytes are a specific immunological target in Rasmussen's encephalitis. Ann Neurol (2007) 1.51
Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins. Lancet (2002) 1.51
Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. Acta Neuropathol (2013) 1.50
Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Int J Cancer (2004) 1.50
Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer (2005) 1.48
Comparison of MELD, Child-Pugh, and Emory model for the prediction of survival in patients undergoing transjugular intrahepatic portosystemic shunting. Am J Gastroenterol (2003) 1.46
Comparison of (18)F-FET and (18)F-FDG PET in brain tumors. Nucl Med Biol (2009) 1.46
Transit time flow measurement in on-pump and off-pump coronary artery surgery. J Thorac Cardiovasc Surg (2003) 1.45
The nuclear receptor tailless induces long-term neural stem cell expansion and brain tumor initiation. Genes Dev (2010) 1.45
Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol (2003) 1.44
ECRG4 is a candidate tumor suppressor gene frequently hypermethylated in colorectal carcinoma and glioma. BMC Cancer (2009) 1.44